Christine Brennan

Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRLV. She was previously on the board of Altimmune (NASDAQ:ALT) and an observer on the boards on a number of companies including ROX Medical, Innocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. She is currently responsible for MRLV investments in Translate Bio and Alector.

Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 and Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also she held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and did post-doctoral research in developmental neurobiology from the National Institutes of Health.